Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Zai Lab up after lung cancer drug meets main goal in late-stage trial

** U.S.-listed shares of China-based drug maker Zai Lab Ltd
 ZLAB.O  jump 3.3% to $16.55 premarket 
    ** ZLab's partner Bristol Myers Squibb  BMY.N  said late on
Thursday that its drug KRAZATI had met the main goal in a
late-stage study for non-small cell lung cancer (NSCLC) with a
mutation
    ** Drug also met a key secondary goal of the study 
    ** ZLAB expects to submit a New Drug Application for KRAZATI
to China's National Medical Products Association for this
indication as second or a later-line treatment this year 
        ** BMY will complete a full evaluation of available data
&  discuss the results with health authorities
    ** Up to Thursday's close, ZLAB's U.S. shares down 41.4% YTD

 (Reporting by Atharva Singh in Bengaluru)
 ((Atharva.singh@thomsonreuters.com))

Recent news on Zai Lab

See all news